Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

Benzinga Newsdesk www.benzinga.com Neutral 61.2%

Neg 0% Neu 61.2% Pos 0%

Goldman Sachs analyst Paul Choi initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $40.